Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Gains from Sales and Divestitures (2020)

Atea Pharmaceuticals (AVIR) has 1 years of Gains from Sales and Divestitures data on record, last reported at $20000.0 in Q4 2020.

  • For Q4 2020, Gains from Sales and Divestitures changed N/A year-over-year to $20000.0; the TTM value through Dec 2020 reached $20000.0, changed N/A, while the annual FY2020 figure was $20000.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $20000.0 in Q4 2020 per AVIR's latest filing.
  • Across five years, Gains from Sales and Divestitures topped out at $20000.0 in Q4 2020 and bottomed at $20000.0 in Q4 2020.